Early stage Alzheimer’s treatments need government action for success: report

A new report has called on governments to improve access to treatments for early-stage Alzheimer's disease. While the drugs lecanemab and donanemab could become available to Canadians in 12-18 months, governments at all levels will need to negotiate pricing and decide on public drug plan inclusion. Early diagnosis and proper infrastructure are crucial for the success of these treatments.

Alzheimer's disease, which affects memory, thinking, and behavior, is the most common cause of dementia, a general term for memory loss and other cognitive issues. The Alzheimer's Society of Ontario's Ngozi Iroanyah highlighted the need for a comprehensive dementia care pathway and public reimbursement to ensure patients receive the necessary care.

Health Canada has approved both lecanemab and donanemab, but the price negotiation and provincial/territorial decisions may delay their availability for public use. Alberta and Ontario governments have been working to prepare for these treatments, with Ontario investing record funds into dementia care. Experts emphasize the importance of early diagnosis and stress that while the treatments can slow disease progression, they do not stop it entirely.